Making Sense of Clinical Trial Data: Is Inverse Probability of Censoring Weighted Analysis the Answer to Crossover Bias?

Correcting for Discretionary Treatment Crossover in an Analysis of Survival in the Breast International Group BIG 1-98 Trial by Using the Inverse Probability of Censoring Weighted Method

(2011) Dianne M. Finkelstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study

(2011) Marco Colleoni et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection

(2010) Judith J Lok et al.   AIDS

Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies.

(2010) JN Ingle et al.   CANCER RESEARCH

Using Marginal Structural Measurement-Error Models to Estimate the Long-term Effect of Antiretroviral Therapy on Incident AIDS or Death

(2009) S. R. Cole et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Estimating ethnic differences in self-reported new use of antidepressant medications: results from the Multi-Ethnic Study of Atherosclerosis

(2009) Joseph A. C. Delaney et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death

(2009) Lauren E. Cain et al.   STATISTICS IN MEDICINE

Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen

(2008) Paul E. Goss et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial

(2008) Jack Cuzick et al.   LANCET ONCOLOGY